News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Aimmune Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Biotech Bay
Bay Area’s Aimmune Gets $145 Million Infusion From Nestlé Health Science
November 4, 2016
·
2 min read
Bio NC
4 Biotech Stocks That Could Triple In Value This Year
August 4, 2016
·
2 min read
Job Trends
NorCal’s Aimmune Signs Lease for Huge Facility in Florida
August 11, 2015
·
2 min read
Deals
Bay Area’s Global Blood Therapeutics, Aimmune Jump on the IPO Wagon Seeking $115 Million Each
July 10, 2015
·
3 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Drug Development
Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years
November 10, 2022
·
14 min read
Business
Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Directly to Patients
October 13, 2022
·
7 min read
Biotech Bay
Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
June 30, 2022
·
10 min read
Drug Development
Aimmune Therapeutics Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for up to 2 Years in the Journal of Allergy and Clinical Immunology
February 16, 2022
·
10 min read
Biotech Bay
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.
November 5, 2021
·
11 min read
Biotech Bay
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
August 4, 2021
·
14 min read
Biotech Bay
Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis
June 8, 2021
·
4 min read
Drug Development
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years
February 25, 2021
·
10 min read
Deals
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
October 13, 2020
·
4 min read
Deals
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
September 14, 2020
·
7 min read
